KT-413, a Novel IRAKIMiD Degrader of IRAK4 and IMiD Substrates, has a Differentiated MOA that Leads to Single-agent and Combination Regressions in MYD88MT Lymphoma Models
June 20, 2021
16th Annual International Conference on Malignant Lymphoma (ICML) Virtual Meeting
Area of Focus
Oncology
Programs
IRAKIMiD (KT-413)
Indications
MYD88 Tumors
Development Stage
Pre-clinical Data
Share
